Results 71 to 80 of about 13,247 (180)

Mesalazine-Induced Myopericarditis in a Patient with a Recent Diagnosis of Crohn’s Disease: Apropos of a Case

Case Reports in Cardiology, 2015
Mesalazine- (5-aminosalicylic acid-) containing products are a well-known treatment for inflammatory bowel disease, often as first line. Myocarditis is recognized as a very rare possible side effect of this drug treatment. We present a case of mesalazine-
Michele Sorleto, Stefanie Dürrwald, Marcus Wiemer   +2 more
doaj   +1 more source

Preparation and evaluation of magnetic microspheres of mesalamine (5-aminosalicylic acid) for colon drug delivery

Journal of Acute Disease, 2013
Objective: To study magnetic microspheres of mesalamine (5-aminosalicylic acid) for colon drug delivery. Methods: Magnetic microspheres were prepared by solvent evaporation technique for use in the application of magnetic carrier technology.
Satinder Kakar, Deepa Batra, Ramandeep Singh   +2 more
doaj   +1 more source

Synthesis and evaluation of mutual azo prodrug of 5-aminosalicylic acid linked to 2-phenylbenzoxazole-2-yl-5-acetic acid in ulcerative colitis

Drug Design, Development and Therapy, 2013
Jamal A Jilani,1 Maha Shomaf,2 Karem H Alzoubi3 1Department of Medicinal Chemistry and Pharmacognosy, Jordan University of Science and Technology, Irbid, Jordan; 2Department of Pathology, Jordan University, Amman, Jordan; 3Department of Clinical Pharmacy,
Jilani JA, Shomaf M, Alzoubi KH
doaj  

Mesalazine use tactics in the ulcerative colitis patients

Российский журнал гастроэнтерологии, гепатологии, колопроктологии, 2013
Aim of the lecture. To specify indications for the administration of the 5-aminosalicylic acid (5-АSA) in the patients with ulcerative colitis (UC) and to discuss the possibility of correlation between the body mass index, the disease activity and ...
A. V. Korolev, O. Z. Okhlobystina, L. N. Androsova, O. S. Shifrin   +3 more
doaj  

The choice of treatment approach for mild and moderate ulcerative colitis: A review

Consilium Medicum
Ulcerative colitis (UC) is a chronic immune-inflammatory disease of unknown etiology characterized by continuous non-granulomatous inflammation of the colon mucosa. Inflammation may be limited to the rectum but often extends to the proximal colon.
Oleg V. Golovenko, Irina D. Loranskaia, Alexey M. Osadchuk   +2 more
doaj   +1 more source

Mayo Endoscopic Subscore at Week 24 Is a Predictor of Future Loss of Response to Vedolizumab in Patients with Ulcerative Colitis in Clinical Remission

Inflammatory Intestinal Diseases
Introduction: Vedolizumab (VDZ) is a gut-selective integrin antagonist approved for the treatment of ulcerative colitis. While its efficacy and safety have been demonstrated in clinical trials, real-world data on long-term treatment ...
Daisuke Saito, Minoru Matsuura, Hiromu Morikubo, Noritaka Hibi, Haruka Komatsu, Noriaki Oguri, Takeshi Fujima, Haruka Wada, Ryota Ogihara, Tatsuya Mitsui, Mari Hayashida, Jun Miyoshi, Teppei Omori, Tadakazu Hisamatsu   +13 more
doaj   +1 more source

Clinical Background Factors as Predictors of the Efficacy of 5-Aminosalicylic Acid Suppositories in Patients with Ulcerative Colitis. [PDF]

Inflamm Intest Dis, 2023
Uchiyama K, Takagi T, Mizushima K, Asaeda K, Kubota-Kajiwara M, Sugaya T, Kashiwagi S, Minagawa Y, Hotta Y, Tanaka M, Inoue K, Katada K, Kamada K, Ishikawa T, Yasuda H, Konishi H, Kishimoto M, Naito Y, Itoh Y.   +18 more
europepmc   +1 more source

Adherence to 5-aminosalicylic acid maintenance treatment in young people with ulcerative colitis: a retrospective cohort study in primary care. [PDF]

Br J Gen Pract, 2023
Jayasooriya N, Pollok RC, Blackwell J, Bottle A, Petersen I, Creese H, Saxena S, POP-IBD study group.   +7 more
europepmc   +1 more source

Antimycobacterial, antimicrobial, and biocompatibility properties of para-aminosalicylic acid with zinc layered hydroxide and Zn/Al layered double hydroxide nanocomposites

Drug Design, Development and Therapy, 2014
Bullo Saifullah,1 Mohamed E El Zowalaty,2,3 Palanisamy Arulselvan,2 Sharida Fakurazi,2,4 Thomas J Webster,5,6 Benjamin M Geilich,5 Mohd Zobir Hussein1 1Materials Synthesis and Characterization Laboratory, Institute of Advanced Technology (ITMA ...
Saifullah B, El Zowalaty ME, Arulselvan P, Fakurazi S, Webster TJ, Geilich BM, Hussein MZ   +6 more
doaj  

Concomitant 5-Aminosalicylic Acid Does Not Affect the Efficacy of Janus Kinase Inhibitors in Ulcerative Colitis. [PDF]

Clin Pharmacol Ther
Tursi A, Pasta A, Elisei W, Barberio B, Mocci G, Maconi G, Gravina AG, Pellegrino R, Bodini G, Savarino EV, Papa A, Italian Network for Inflammatory Bowel Diseases (IN‐IBD).   +11 more
europepmc   +1 more source